OakChart

Akari Therapeutics Plc ADR

AKTXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:05 PM ET

7.45+0.32 (4.49%)
2026-11-12 06:44 CET
Market cap
13.04 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-30.90 USD m
Free cash flow, TTM
-10.74 USD m
EPS diluted, TTM
-17.25
P/E
-
Compare

Price

AKTX against its 20, 50 and 200-day averages
2050200miss
10.0020.0030.0017.0M34.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AKTXclose 7.4520-day 8.2850-day 9.08200-day 8.947.4552w high52w low

74.6% under the 52-week high of 29.32 on 28 May 2026. 52-week low 3.02 on 12 May 2026. Last 15 sessions, 42.3% high to low

Volume 0.35× normal · the line is the 50-bar volume average

Profile

AKTX
52-week range, 17% of the way up
3.0229.32

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Employees6
IPOMay 07, 2013
Beta1.48
ATR, 14d1.02
Rel volume0.35
Short float1.03%
Insider own0.40%
Inst own9.75%

Snapshot

6 groups

Valuation

Index-
Market Cap13.04M
Enterprise Value5.98M
Income-30.90M
Sales0.00M
Book/sh10.62
Cash/sh4.43
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees6
IPOMay 07, 2013

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B0.70
P/C1.68
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.60
Current Ratio0.60
Debt/Eq0.04
LT Debt/Eq0.00
Option/ShortYes / Yes

Earnings

EPS (ttm)-17.25
EPS next Y-5.49
EPS next Q-2.23
EPS this Y52.32%
EPS next Y44.32%
EPS next 5Y46.65%
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q1.39%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.100.00% -

Ownership

Insider Own0.40%
Insider Trans0.00%
Inst Own9.75%
Inst Trans284.19%
ROA-69.02%
ROE-139.80%
ROIC-166.16%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-10.01%
SMA50-17.96%
SMA200-16.68%
Trades-

Technical

Shs Outstand1.75M
Shs Float1.74M
Short Float1.03%
Short Ratio0.28
Short Interest0.02M
52W High29.32 -74.59%
52W Low3.02 147.10%
Volatility12.33% 13.15%
ATR (14)1.02
RSI (14)44.62
Beta1.48
Rel Volume0.35
Avg Volume64.31K
Volume22,514

Performance

Perf Week-19.81%
Perf Month-5.70%
Perf Quarter6.43%
Perf Half Y136.51%
Perf YTD-35.55%
Perf Year-68.51%
Perf 3Y-94.49%
Perf 5Y-99.44%
Perf 10Y-99.89%
Recom1.00
Target Price25.50
Prev Close7.13
Price7.45
Change %4.49%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jul 20, 2026UpgradeMMaxim GroupHold → Buy$30+302.7%
Apr 08, 2026DowngradeMMaxim GroupBuy → Hold
Jan 05, 2026InitiatedLLadenburg ThalmannBuy$1-86.6%
Jul 18, 2025InitiatedMMaxim GroupBuy$5-32.9%
Jan 04, 2019UpgradeBB. Riley FBRNeutral → Buy$2.50 → $3-59.7%
Feb 08, 2018InitiatedBB. Riley FBR, Inc.Neutral$3-59.7%
Sep 22, 2017UpgradeWWilliam BlairMkt Perform → Outperform
May 31, 2017UpgradeCChardan Capital MarketsSell → Neutral$6-19.5%
Apr 17, 2017ReiteratedCChardan Capital MarketsSell$6.50 → $5-32.9%
Jul 11, 2016InitiatedCChardan Capital MarketsSell$5-32.9%

Peers

Mkt cap
TickerCompanyMkt cap
PYXSPyxis Oncology Inc196.16M
STROSutro Biopharma Inc170.12M
BCYCBicycle Therapeutics Plc ADR186.57M
CTMXCytomX Therapeutics Inc464.35M
ZYMEZymeworks BC Inc2.02B
ALXOAlx Oncology Holdings Inc154.87M
ADCTAdc Therapeutics SA204.27M
FHTXFoghorn Therapeutics Inc125.32M
CGENCompugen Ltd197.98M
NVCTNuvectis Pharma Inc722.17M

Insider trading

4 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Patel Sandip IDirectorOct 14 '26Option Exercise0.0010,052438,877Oct 16 05:20 PM
Bazemore Robert BDirectorOct 14 '26Option Exercise0.003,866222,759Oct 16 05:20 PM
Gaslightwala AbizerCEOOct 14 '26Option Exercise0.0027,0661141,173Oct 16 05:20 PM
Patel Samir RashmikantDirectorJul 07 '26Option Exercise0.4322,4749,68198,241Jul 17 06:03 AM

News

latest 14 of 200
  • Akari Therapeutics Participates in Virtual Investor "What This Means" Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho (GlobeNewswire)
  • Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit (GlobeNewswire)
  • Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner (GlobeNewswire) +21.43%
  • Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering (GlobeNewswire) -7.49%
  • Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers (GlobeNewswire)
  • Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums (GlobeNewswire)
  • Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
  • Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy (GlobeNewswire) +5.04%
  • Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform (GlobeNewswire) +7.71%
  • Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation (GlobeNewswire) +5.84%
  • Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology Opportunity (GlobeNewswire) +5.54%
  • Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics (GlobeNewswire) -12.80%
  • Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board (GlobeNewswire) +42.02%
  • Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory Milestones (GlobeNewswire) -9.69%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-130.000-1.040-2.6800.00-1
2026Q12026-05-14-9.740-1.330-9.7400.000.001
2025Q42026-04-07-2.990-1.800-0.000.002
2025Q32025-12-05-4.000-1.600-7.7890.000.001
2025Q22025-09-25-4.000-3.600-2.4380.000.002
2025Q12025-05-15-5.400--5.4510.00--
2024Q22024-08-190.000--32.1350.00--
2024Q12024-05-160.000-0.0000.00--
2023S12023-09-290.000-----
2022Q22022-09-270.000--76.132---
2022Q12022-07-200.000--77.156---
2021Q32021-12-030.000--24.689---
2021Q22021-09-220.000--90.223--1
2021Q12021-06-290.0000.000-122.020.000.001
2020Q42021-04-21-8.0000.000-142.81--1
2020Q32020-12-110.0000.00035.0170.000.00-

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-8.000-8.000-739.050.000.00
2020FY-8.000-8.000-436.17--
2021FY0.000--324.76--
2022FY0.000-296-227.06-0.00
2023FY0.000--82.1070.00-
2024FY-56.400--66.3070.00-
2025FY-20.680-7.000-20.6800.000.00
2026FY--9.860--0.00
2027FY--5.490---
2028FY--3.140---
2029FY--3.620---
2030FY--4.120---

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-08-141000.000.000.00
2026Q3S2026-05-141000.000.000.00
2026Q3S2026-04-071000.000.000.00
2026Q3S2025-12-051000.000.000.00
2026Q3S2025-11-121000.000.000.00
2026Q3S2025-11-111000.000.000.00
2026Q3S2025-11-101000.000.000.00
2026Q3S2025-11-091000.000.000.00
2026Q3S2025-11-081000.000.000.00
2026Q3S2025-11-071000.000.000.00
2026Q3S2025-11-061000.000.000.00
2026Q3S2025-11-051000.000.000.00
2026Q3S2025-11-041000.000.000.00
2026Q3S2025-11-031000.000.000.00

Estimate history

EPS, annual-2425.733-853.754-739.047-436.167-324.761-227.06-82.107-66.307-20.602-17.2467
Period201720182019202020212022202320242025TTM
EPS, quarterly-32.135-9.595--5.451-2.438-7.789--9.584-2.404
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.0190.020.0280.0480.0590.0930.1650.6651.1321.75
Period201720182019202020212022202320242025MRQ
Shares, quarterly0.3040.3040.6650.7220.8150.8151.1321.1451.75
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.010.000.000.000.010.020.04
Gross Profit0.000.00-0.01-0.00-0.00-0.00-0.01-0.02-0.04
Selling, General and Administrative Excl. Other13.6612.1216.6416.8725.3920.2721.5124.9522.62
Research and Development4.872.826.995.4711.8712.2012.2916.7211.78
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-13.66-12.12-16.65-16.87-25.39-20.28-21.52-24.97-22.65
Interest Expense0.980.950.240.000.000.000.000.000.00
Unusual Expense17.644.602.91-6.62-4.980.00-0.56-0.20-5.93
Net Income Before Taxes-32.75-18.34-19.80-10.05-20.05-20.49-20.61-24.86-16.44
Income Taxes-1.85-1.010.000.00-2.32-3.07-3.40-7.940.00
Consolidated Net Income-30.90-17.34-19.80-10.05-17.74-17.42-17.21-16.92-16.44
Net Income From Continuing Operations-30.90-17.34-19.80-10.05-17.74-17.42-17.21-16.92-16.44
Net Income-30.90-17.34-19.80-10.05-17.74-17.42-17.21-16.92-16.44
EPS (Recurring)-10.35-16.78-59.48-120.00-271.94-324.73-445.89-745.20-1,069.35
EPS (Basic, Before Extraordinaries)-----227.06-324.76-436.17-739.05-853.75
EPS (Diluted)-17.25-20.60-66.31-82.11-227.06-324.76-436.17-739.05-853.75
EBITDA-13.66-12.12-16.64-16.87-25.39-20.27-21.51-24.95-22.62
Non-Operating Income (Expense)-0.46-0.670.010.200.36-0.210.35-0.080.29
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.712.292.251.150.730.310.331.051.65
Shares Outstanding1.751.130.660.170.090.060.050.030.02
Market Capitalization13.0413.0432.4415.7927.8971.4071.1839.3024.82

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.000.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.00-0.000.00
Selling, General and Administrative Excl. Other4.613.623.222.213.163.544.251.87
Research and Development2.081.461.080.250.680.821.240.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-4.61-3.62-3.22-2.21-3.16-3.54-4.26-1.87
Interest Expense0.080.060.720.120.050.060.120.07
Unusual Expense0.1011.670.795.09-1.340.00-0.571.06
Net Income Before Taxes-4.82-15.29-5.21-7.44-1.92-3.72-3.74-2.92
Income Taxes0.00-0.860.08-1.080.000.000.000.00
Consolidated Net Income-4.82-14.43-5.29-6.36-1.92-3.72-3.74-2.92
Net Income From Continuing Operations-4.82-14.43-5.29-6.36-1.92-3.72-3.74-2.92
Net Income-4.82-14.43-5.29-6.36-1.92-3.72-3.74-2.92
EPS (Recurring)-2.65-4.22--3.43-3.63-5.45--7.17
EPS (Basic, Before Extraordinaries)-2.40-9.58------
EPS (Diluted)-2.40-9.58--7.79-2.44-5.45--9.59
EBITDA-4.61-3.62-3.22-2.21-3.16-3.54-4.25-1.87
Non-Operating Income (Expense)-0.030.06-0.47-0.02-0.05-0.130.070.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.560.240.370.540.731.021.240.25
Shares Outstanding1.751.141.130.820.820.720.660.30
Market Capitalization13.045.8913.0832.9438.1635.8132.4435.83

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments5.262.663.8513.259.3614.065.735.4528.11
Short Term Receivables0.010.200.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.180.090.500.562.260.520.711.420.71
Total Current Assets5.462.954.3413.8111.6314.586.446.8728.81
Net Property, Plant & Equipment0.000.000.000.000.000.000.010.020.06
Total Investments and Advances0.000.000.000.000.000.000.000.520.14
Intangible Assets42.4347.610.010.020.020.030.030.030.04
Deferred Tax Assets0.110.10-------
Other Assets0.000.000.000.000.000.000.000.580.00
Total Assets48.0050.664.3613.8311.6514.606.488.0329.05
Short Term Debt Incl. Current Port. of LT Debt0.753.260.000.000.000.000.000.000.00
Accounts Payable0.000.000.000.000.000.000.000.000.00
Other Current Liabilities11.6016.654.5812.046.095.226.474.9211.85
Total Current Liabilities12.3519.914.5812.046.095.226.474.9211.85
Long Term Debt0.000.000.000.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities7.068.14-------
Other Liabilities0.260.380.000.000.000.000.000.000.05
Total Liabilities19.6728.434.5812.046.095.226.474.9211.90
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity28.3322.23-0.231.795.559.380.013.1117.15
Total Shareholders Equity28.3322.23-0.231.795.559.380.013.1117.15
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity28.3322.23-0.231.795.559.380.013.1117.15
Total Liabilities & Stockholders Equity48.0050.664.3613.8311.6514.606.488.0329.05
Book Value Per Share25.0333.44-1.3819.2493.36195.130.27157.46899.47
Tangible Book Value Per Share-12.46-38.18-1.4719.0692.97194.57-0.80155.80897.42
Full-Time Employees69-1598101418
Price to Book Ratio0.701.465.683.3512.857.58-22.177.983.91
Return on Assets-35.15-71.98-110.49-139.23-132.73-160.83-233.17-88.67-95.51
Return on Equity-68.59-179.99-1,286.61-482.95-233.25-452.31-1,084.74-162.24-139.61
Return on Invested Capital-61.21-89.07--990.49-313.65-183.44-222,636.74-528.36-208.57
Quick Ratio0.440.150.951.151.912.791.001.402.43
Current Ratio0.440.150.951.151.912.791.001.402.43

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-30.95-17.34-19.80-10.05-17.74-17.42-17.21-16.92-16.44
Depreciation-0.000.010.000.000.000.010.020.04
Other Funds (Non Cash)21.078.240.69-5.58-4.580.560.180.82-1.69
Funds from Operations-11.83-10.19-19.10-15.63-22.31-16.86-17.03-16.08-18.09
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital1.09-0.406.54-0.870.82-1.98-0.063.10-4.45
Cash from Operating Activities-10.74-10.59-12.56-16.50-21.49-18.84-17.08-12.97-22.54
Capital Expenditures0.000.000.000.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.380.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.000.380.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock16.3913.9311.857.0525.2714.2925.2712.700.31
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock16.3913.9311.857.0525.2714.2925.2712.700.31
Proceedsfrom Stock Options16.3913.9311.857.0525.1814.2925.2412.700.31
Issuance or Reduction of Debt, Net-0.66-1.05-0.860.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.000.330.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities15.7313.2010.997.0525.2714.2925.2712.700.31
Exchange Rate Effect-0.00-0.000.010.11-0.140.200.03-0.01
Net Change in Cash4.992.61-1.19-9.443.89-4.698.39-0.24-22.24
Free Cash Flow-10.74-10.59-12.56-16.50-21.49-18.84-17.08-12.97-22.54
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit--1.090.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments7.752.835.262.542.772.64
Short Term Receivables0.000.000.010.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.570.760.180.400.530.71
Total Current Assets8.323.595.462.953.303.35
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets30.3030.3042.4342.4347.6147.61
Deferred Tax Assets--0.11---
Other Assets0.000.000.000.000.000.00
Total Assets38.6233.8948.0045.3850.9150.96
Short Term Debt Incl. Current Port. of LT Debt0.690.730.752.121.551.85
Accounts Payable0.000.000.000.000.000.00
Other Current Liabilities13.2412.6811.6013.4515.5919.06
Total Current Liabilities13.9413.4112.3515.5717.1420.91
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities6.096.097.066.958.048.04
Other Liabilities0.000.000.260.170.130.27
Total Liabilities20.0319.5119.6722.6925.3129.21
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity18.5914.3828.3322.6925.6121.75
Total Shareholders Equity18.5914.3828.3322.6925.6121.75
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity18.5914.3828.3322.6925.6121.75
Total Liabilities & Stockholders Equity38.6233.8948.0045.3850.9150.96
Book Value Per Share10.6212.5625.0327.8231.4030.12
Tangible Book Value Per Share-6.69-13.91-12.46-24.21-26.99-35.83
Full-Time Employees--6---
Price to Book Ratio0.700.410.461.451.491.65
Return on Assets-69.02-66.00-35.05-65.41-43.94-66.80
Return on Equity-139.80-155.01-68.39-196.77-112.31-197.30
Return on Invested Capital-25.90-100.35-18.68-28.03-7.49-17.10
Quick Ratio0.600.270.440.190.190.16
Current Ratio0.600.270.440.190.190.16

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-4.83-14.43-5.30-6.40-1.94-3.71
Depreciation--0.000.000.000.00
Other Funds (Non Cash)0.9011.972.235.96-0.940.99
Funds from Operations-3.93-3.32-3.06-1.52-2.89-2.72
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.820.840.02-0.58-0.410.57
Cash from Operating Activities-3.11-2.48-3.04-2.10-3.30-2.15
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.240.197.99-0.034.411.56
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock8.240.197.99-0.034.411.56
Proceedsfrom Stock Options8.240.197.99-0.034.411.56
Issuance or Reduction of Debt, Net-0.20-0.13-2.231.91-0.22-0.51
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.00-0.00-0.761.09
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.030.055.761.883.432.13
Exchange Rate Effect---0.00-0.000.000.00
Net Change in Cash4.92-2.432.73-0.230.13-0.02
Free Cash Flow-3.11-2.48-3.04-2.10-3.30-2.15

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.03%0.0M1.7M62.12K
2026-10-151.01%0.0M1.7M61.36K
2026-09-300.84%0.0M1.7M66.34K
2026-09-150.62%0.0M1.7M75.90K
2026-08-311.73%0.0M1.7M74.15K
2026-08-142.16%0.0M1.7M784.56K
2026-07-312.39%0.0M1.1M783.95K
2026-07-151.44%0.0M1.1M803.80K
2026-06-301.58%0.0M1.1M787.76K
2026-06-153.95%0.0M1.1M758.65K
2026-05-2910.66%0.1M1.1M756.39K
2026-05-155.67%0.1M1.1M33.48K
2026-04-300.04%0.0M45.1M28.32K
2026-04-150.03%0.0M45.1M15.73K
2026-03-310.02%0.0M32.5M9.29K
2026-03-130.52%0.0M0.8M18.12K
2026-02-270.64%0.0M0.8M26.98K
2026-02-130.77%0.0M0.8M26.57K
2026-01-300.74%0.0M0.8M29.07K
2026-01-150.65%0.0M0.8M27.38K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call5.001.204.700.009.6010.000.000.842-0.1480.003
call7.500.002.950.006.7310.000.000.695-0.1530.004
call10.000.003.500.00-0.000.00---
call12.500.003.200.009.1140.000.000.634-0.2240.004
call15.000.003.200.009.8250.000.000.620-0.2450.004
put5.000.002.200.009.3670.000.00-0.158-0.1480.003
put7.500.002.951.806.5763.000.00-0.305-0.1520.004
put10.001.404.800.006.5420.000.00-0.344-0.1950.004
put12.503.707.200.007.3120.000.00-0.366-0.2230.004
put15.006.209.700.008.0440.000.00-0.380-0.2430.004

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-30S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-308-KCurrent report2026-10-28SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-164Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-10-144Statement of changes in beneficial ownership of securities2026-10-12SEC
2026-10-143Initial statement of beneficial ownership of securities2026-10-12SEC
2026-10-01DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-01SEC
2026-10-014Statement of changes in beneficial ownership of securities2026-09-29SEC
2026-10-018-KCurrent report2026-09-29SEC
2026-08-194Statement of changes in beneficial ownership of securities2026-08-17SEC
2026-08-138-KCurrent report2026-08-13SEC
2026-08-1310-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-12SCHEDULE 13GSEC
2026-08-07SCHEDULE 13GSEC
2026-08-054Statement of changes in beneficial ownership of securities2026-07-16SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-13EFFECTEffectiveness filing by commission orderSEC
2026-07-10S-3/ASEC
2026-07-08S-3/ASEC
2026-07-07EFFECTEffectiveness filing by commission orderSEC
2026-07-028-KCurrent report2026-06-30SEC
2026-07-02S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-06-268-KCurrent report2026-06-23SEC
2026-06-26S-1/ASEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-24SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MMCAP International Inc. SPC8.74%
Cresset Asset Management, LLC1.80%
JANE STREET GROUP, LLC1.35%
HRT FINANCIAL LP1.20%
Occidental Asset Management, LLC1.04%
GAMMA Investing LLC0.14%
IFP Advisors, Inc0.01%
Nuveen, LLC0.00%
SBI Securities Co., Ltd.0.00%
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO0.00%

Funds

Fund% owned
-

OakChart. AKTX. Cached 15 minutes.